Recent research on MCL-1, a critical protein that is an attractive target for cancer drug development, helps explain why some ...

Landmark research on MCL-1, a critical protein that is an attractive target for cancer drug development, helps explain why ...

BeOne Medicines has secured approval from the EC for Tevimbra (tislelizumab) to be used along with gemcitabine and cisplatin to treat NPC.

Libtayo works by attaching itself to a receptor called programmed cell death protein 1 (PD-1) on specific immune system cells called T cells. PD-1 can show up on these cells when cancer has ...

The findings clarify that side effects of cancer treatments may be linked to a specific protein’s critical role in cellular ...

A collaborative study from the University of Cologne has uncovered how a key mitochondrial protein, AIFM1 (Apoptosis-Inducing ...

Results described in the paper more generally suggest that the molecular mechanism of programmed cell death has been conserved evolutionarily from worms to mammals. "Concerning evolutionary ...

Scientists at UC Davis discovered a small genetic difference that could explain why humans are more prone to certain cancers ...

As a result, drugs that inhibit MCL-1 can inadvertently damage healthy tissues that rely on this protein for energy, especially in organs with high energy demand like the heart and liver, leading to ...

A pioneering discovery at WEHI in 1988 of a protein that stopped programmed cell death sparked huge interest in the field, and has since led to a new drug to treat cancer.